NEK9-dependent proliferation of cancer cells lacking functional p53

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Kurioka, Daisuke ^a,d   Takeshita, Fumitaka ^a   Tsuta, Koji ^b   Sakamoto, Hiromi ^a   Watanabe, Shun Ichi ^b   Matsumoto, Kenji ^c   Watanabe, Masatoshi ^d   Nakagama, Hitoshi ^a   Ochiya, Takahiro ^a   Yokota, Jun ^a,e   Kohno, Takashi ^a   Tsuchiya, Naoto ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d YOKOHAMA NATIONAL UNIVERSITY   (Japan)

^e Institute of Predictive and Personalized Medicine of Cancer IMPPC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; MICRORNA; MIRN22 MICRORNA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 14; NEK9 PROTEIN, HUMAN; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA;

ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL AGING; CELL PROLIFERATION; DRUG SCREENING; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENETICS; HUMAN; LUNG TUMOR; MORTALITY; MOUSE; NUDE MOUSE; RNA INTERFERENCE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE 14; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906251438     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06111     Document Type: Article

References (38)

1. Vousden, K.H. & Prives, C. Blinded by the Light: The Growing Complexity of p53. Cell 137, 413-431 (2009).
2. Harris, S. L. & Levine, A. J. The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899-2908 (2005). (Pubitemid 40638098)
3. Watson, I. R., Takahashi, K., Futreal, P. A. & Chin, L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet 14, 703-718 (2013).
4. Muller, P. A. & Vousden, K. H. p53 mutations in cancer. Nat Cell Biol 15, 2-8 (2013).
5. Vousden, K. H. & Prives, C. P53 and prognosis: new insights and further complexity. Cell 120, 7-10 (2005). (Pubitemid 40094596)
6. Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev 26, 1268-1286 (2012).
7. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
8. Calin, G. A. & Croce, C. M. MicroRNA signatures in human cancers. Nat Rev Cancer 6, 857-866 (2006). (Pubitemid 44629897)
9. van Kouwenhove, M. Kedde, M. & Agami, R. MicroRNA regulation by RNAbinding proteins and its implications for cancer. Nat Rev Cancer 11, 644-656 (2011).
10. Hermeking, H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 12, 613-626 (2012).
11. Lujambio, A. & Lowe, S. W. The microcosmos of cancer. Nature 482, 347-355 (2012).
12. He, L. et al. A microRNA component of the p53 tumour suppressor network. Nature 447, 1130-1134 (2007). (Pubitemid 47014436)
13. Raver-Shapira, N. et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26, 731-743 (2007). (Pubitemid 46856247)
14. Tazawa, H., Tsuchiya, N., Izumiya, M. & Nakagama, H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 104, 15472-15477 (2007). (Pubitemid 47502941)
15. Tsuchiya, N. et al. Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. Cancer Res 71, 4628-4639 (2011).
16. Tan, B. C. & Lee, S. C. Nek9, a novel FACT-associated protein, modulates interphase progression. J Biol Chem 279, 9321-9330 (2004). (Pubitemid 38295996)
17. Belham, C. et al. Amitotic cascade of NIMA family kinases. Nercc1/Nek9 activates the Nek6 and Nek7 kinases. J Biol Chem 278, 34897-34909 (2003). (Pubitemid 37102249)
18. Richards, M. W. et al. An autoinhibitory tyrosine motif in the cell-cycle-regulated Nek7 kinase is released through binding of Nek9. Mol Cell 36, 560-570 (2009).
19. Sdelci, S., Bertran, M. T. & Roig, J. Nek9, Nek6, Nek7 and the separation of centrosomes. Cell cycle 10, 3816-3817 (2011).
20. Yang, S. W. et al. Nek9 regulates spindle organization and cell cycle progression during mouse oocyte meiosis and its location in early embryo mitosis. Cell cycle 11, 4366-4377 (2012).
21. Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J. & Toussaint, O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nature Protoc 4, 1798-1806 (2009).
22. McDonald, E. R. 3rd., Wu, G. S., Waldman, T. & El-Deiry, W. S. Repair Defect in p21 WAF1/CIP1 -/- human cancer cells. Cancer Res 56, 2250-2255 (1996).
23. Abbas, T. & Dutta, A. p21 in cancer: intricate networks andmultiple activities. Nat Rev Cancer 9, 400-414 (2009).
24. Comes, F. et al. A novel cell type-specific role of p38alpha in the control of autophagy and cell death in colorectal cancer cells. Cell Death and differentiation 14, 693-702 (2007). (Pubitemid 46444507)
25. Wagner, E. F. & Nebreda, A. R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9, 537-549 (2009).
26. Paillas, S. et al. MAPK14/p38alpha confers irinotecan resistance to TP53-defective cells by inducing survival autophagy. Autophagy 8, 1098-1112 (2012).
27. Iggo, R., Gatter, K., Bartek, J., Lane, D. & Harris, A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335, 675-679 (1990). (Pubitemid 20089305)
28. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
29. Roig, J., Mikhailov, A., Belham, C. & Avruch, J. Nercc1, a mammalian NIMAfamily kinase, binds the Ran GTPase and regulates mitotic progression. Genes Dev 16, 1640-1658 (2002). (Pubitemid 34743325)
30. O'Regan, L. & Fry, A. M. The Nek6 and Nek7 protein kinases are required for robust mitotic spindle formation and cytokinesis. Mol Cell Biol 29, 3975-3990 (2009).
31. Rapley, J. et al. The NIMA-family kinase Nek6 phosphorylates the kinesin Eg5 at a novel site necessary for mitotic spindle formation. J Cell Sci 121, 3912-3921 (2008).
32. Bertran, M. T. et al. Nek9 is a Plk1-activated kinase that controls early centrosome separation through Nek6/7 and Eg5. EMBO J 30, 2634-2647 (2011).
33. Sdelci, S., Bertran, M. T. & Roig, J. Nek9, Nek6, Nek7 and the separation of centrosomes. Cell cycle 10, 3816-3817 (2011).
34. Sur, S. et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 106, 3964-3969 (2009).
35. Roig, J., Groen, A., Caldwell, J. & Avruch, J. Active Nercc1 protein kinase concentrates at centrosomes early in mitosis and is necessary for proper spindle assembly. Mol Biol Cell 16, 4827-4840 (2005). (Pubitemid 41416463)
36. Muller, P. A. & Vousden, K. H. Mutant p53 in Cancer: New Functions and Therapeutic Opportunities. Cancer Cell 25, 304-317 (2014).
37. Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R. & Lane, D. P. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9, 862-873 (2009).
38. Cheok, C. F., Verma, C. S., Baselga, J. & Lane, D. P. Translating p53 into the clinic. Nat Rev Clin Oncol 8, 25-37 (2011).